Market Update (NASDAQ:AMGN): Amgen To Present Repatha® (Evolocumab) Data At ACC.16

[PR Newswire] – THOUSAND OAKS, Calif., March 21, 2016 /PRNewswire/ — Amgen ( NASDAQ:AMGN ) today announced that it will present 19 abstracts related to its cardiovascular portfolio, including new detailed data evaluating … Read more on this. Amgen Inc. (AMGN) , valued at $110.56B, started trading this morning at $145.30. A quick look at the market, the company’s stock traded between $145.02 and $147.95 and has traded between $130.09 and $181.81 over the past 12 months. Amgen (AMGN) shares are currently priced at 13.32x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -2.42x earnings multiple for the same period. The company pays shareholders $4.00 per share in dividend income per year, for a current yield of 2.75%. In a review of the consensus earnings estimate this quarter, 20 sell-side analysts are looking at $2.59 per share, which would be $0.11 better than the year-ago quarter and a $0.03 sequential increase. Investors should also note that the full-year EPS estimate of $10.82 is a $0.44 better when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.29 Billion. If reported, that would be a 5.17% increase over the year-ago quarter. Recently, Citigroup Initiated AMGN at Neutral (Feb 25, 2016). Previously, Credit Suisse Initiated AMGN at to Outperform. Investors should keep in mind is that the average price target is $180.71, which is 24.37% above where the stock opened this morning. See more in (NASDAQ:AMGN) Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 2016 Second Quarter Dividend Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol Stock Update (NASDAQ:AMGN): Amgen To Present At The Credit Suisse 24th Annual Healthcare Conference